- Home
- SNT vs PROK Comparison
SNT vs PROK Comparison
Compare SNT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- PROK
- Stock Information
- Founded
- SNT 1965
- PROK 2015
- Country
- SNT Canada
- PROK United States
- Employees
- SNT N/A
- PROK N/A
- Industry
- SNT Telecommunications Equipment
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNT Telecommunications
- PROK Health Care
- Exchange
- SNT Nasdaq
- PROK Nasdaq
- Market Cap
- SNT 95.2M
- PROK 85.5M
- IPO Year
- SNT 1993
- PROK N/A
- Fundamental
- Price
- SNT $5.04
- PROK $0.64
- Analyst Decision
- SNT
- PROK Hold
- Analyst Count
- SNT 0
- PROK 3
- Target Price
- SNT N/A
- PROK $3.50
- AVG Volume (30 Days)
- SNT 110.4K
- PROK 1.7M
- Earning Date
- SNT 08-25-2025
- PROK 08-08-2025
- Dividend Yield
- SNT N/A
- PROK N/A
- EPS Growth
- SNT N/A
- PROK N/A
- EPS
- SNT 0.18
- PROK N/A
- Revenue
- SNT $36,690,000.00
- PROK $306,000.00
- Revenue This Year
- SNT N/A
- PROK $54.34
- Revenue Next Year
- SNT N/A
- PROK N/A
- P/E Ratio
- SNT $26.28
- PROK N/A
- Revenue Growth
- SNT 8.36
- PROK N/A
- 52 Week Low
- SNT $1.40
- PROK $0.46
- 52 Week High
- SNT $5.04
- PROK $2.59
- Technical
- Relative Strength Index (RSI)
- SNT 70.52
- PROK 43.63
- Support Level
- SNT $4.30
- PROK $0.54
- Resistance Level
- SNT $4.84
- PROK $0.90
- Average True Range (ATR)
- SNT 0.28
- PROK 0.13
- MACD
- SNT 0.04
- PROK -0.02
- Stochastic Oscillator
- SNT 100.00
- PROK 20.25
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.